If environmentalists have their way, the flame in Chesapeake Energy's (CHK $23.79) "green" logo would be snuffed out. Critics howl that the energy company's drilling method (like all shale exploration companies), known as hydraulic fracturing, used to extract its gas deposits is toxic. Thanks to dead cows, water well explosions, and contaminated groundwater from drilling, Chesapeake Energy's effort to market natural gas as an environmentally friendly option to "filthy coal" hasn't gained much traction lately. 
Share:  If environmentalists have their way, the flame in <span class="company">Chesapeake Energy</span>'s (CHK $23.79) "green" logo would be snuffed out. Critics howl that the energy company's drilling method (like all shale exploration companies), known as hydraulic fracturing, used to extract its gas deposits is toxic. Thanks to dead cows, water well explosions, and contaminated groundwater from drilling, <span class="company">Chesapeake Energy</span>'s effort to market natural gas as an environmentally friendly option to "filthy coal" hasn't gained much traction lately. Tweet this 

Comparable same store sales at Burger King (BKC $17.90) operations in North America (more than 7,500 stores) declined three percent versus a year ago. Consumers are eating out less in this economy — and when dining out they are choosing less expensive restaurants. With the price value proposition shifting to the value side, Burger King needs to figure out how to retain customers — and their loyalty – in an industry dominated by burger pricing wars. 
Share:  Comparable same store sales at <span class="company">Burger King</span> (BKC $17.90) operations in North America (more than 7,500 stores) declined three percent versus a year ago. Consumers are eating out less in this economy — and when dining out they are choosing less expensive restaurants. With the price value proposition shifting to the value side, <span class="company">Burger King</span> needs to figure out how to retain customers — and their loyalty – in an industry dominated by burger pricing wars. Tweet this 

In 2009, First Solar (FSLR $105.90) generated almost 65 percent of its $2.06 billion in sales from German photovoltaic (PV) projects, from roof top panels to arrays of solar panels on farms, according to its annual regulatory filing. In 2010, the cadmium telluride (CdTe) thin film module manufacturer will still derive about 40 percent to 50 percent of module sales from German customers, despite best efforts to open windows to other sunshine markets. Most of its business from Germany will be front loaded, CEO Robert Gillette said on the fourth quarter ending 2009 earnings call, to beat the planned feed in subsidy cuts. 
Share:  In 2009, <span class="company">First Solar</span> (FSLR $105.90) generated almost 65 percent of its $2.06 billion in sales from German photovoltaic (PV) projects, from roof top panels to arrays of solar panels on farms, according to its annual regulatory filing. In 2010, the cadmium telluride (CdTe) thin film module manufacturer will still derive about 40 percent to 50 percent of module sales from German customers, despite best efforts to open windows to other sunshine markets. Most of its business from Germany will be front loaded, CEO Robert Gillette said on the fourth quarter ending 2009 earnings call, to beat the planned feed in subsidy cuts. Tweet this 

Petrohawk Energy (HK $22.16) is nursing a mighty hangover after awaking from a 2 ½ year buying binge — $5 billion spent on acquiring leasehold interests in unconventional pay zones, specifically the Haynesville Shale, Fayetteville Shale, and Eagle Ford Shale plays. Petrohawk is like the US Treasury in some respects, having funded its expansive appetite with paper — common stock outstanding has almost doubled since 2006 to 300 million shares — and deficit spending: At , long term stood at approximately $24 billion, roughly 73 percent of stockholder equity And, interest expense to service this debt totaled $174 million through September, up from $884 million in all of 2006, according to regulatory filings 
Share:  <span class="sent"><span class="company">Petrohawk Energy</span> (HK $22.16) is nursing a mighty hangover after awaking from a 2 ½ year buying binge — $5 billion spent on acquiring leasehold interests in unconventional pay zones, specifically the Haynesville Shale, Fayetteville Shale, and Eagle Ford Shale plays. </span> Petrohawk is like the US Treasury in some respects, having funded its expansive appetite with paper — common stock outstanding has almost doubled since 2006 to 300 million shares — and deficit spending: At , long term stood at approximately $24 billion, roughly 73 percent of stockholder equity And, interest expense to service this debt totaled $174 million through September, up from $884 million in all of 2006, according to regulatory filings Tweet this 

Celgene (CELG $60.11) chief executive Sol Barer predicts Revlimid will win regulatory approval as front line treatment for newly diagnosed multiple myeloma (MM) patients in both U.S and European markets. However, to win broader labeling and expand its European footprint, Celgene's best selling product will need to show a six to eight month difference in progression free survival to be considered significant, said oncologists surveyed by Pharmawire Wall Street analysts are falling all over each other to trumpet the growth prospects for the drug with approved maintenance dose settings 
Share:  <span class="sent"><span class="company">Celgene</span> (CELG $60.11) chief executive Sol Barer predicts Revlimid will win regulatory approval as front line treatment for newly diagnosed multiple myeloma (MM) patients in both U.S and European markets. </span> However, to win broader labeling and expand its European footprint, <span class="company">Celgene</span>'s best selling product will need to show a six to eight month difference in progression free survival to be considered significant, said oncologists surveyed by Pharmawire Wall Street analysts are falling all over each other to trumpet the growth prospects for the drug with approved maintenance dose settings Tweet this 

Suncor Energy (SU $30.05) is a long way from achieving the significant synergies envisioned from its all stock C$19.63 billion acquisition of Petro Canada last August: Net debt increased to 4.8 times cash flow from operations at year end 2009, from 1.8 times in 2008. Return on employed capital, excluding major projects in progress (such as its Firebag bitumen in situ mining operations) plummeted to 26 percent, from 225 percent in the prior year Can Suncor control operating costs and get its debt paid down towards the $10 billion range by the end of 2010? 
Share:  <span class="sent"><span class="company">Suncor Energy</span> (SU $30.05) is a long way from achieving the significant synergies envisioned from its all stock C$19.63 billion acquisition of Petro Canada last August: Net debt increased to 4.8 times cash flow from operations at year end 2009, from 1.8 times in 2008. </span> Return on employed capital, excluding major projects in progress (such as its Firebag bitumen in situ mining operations) plummeted to 26 percent, from 225 percent in the prior year Can Suncor control operating costs and get its debt paid down towards the $10 billion range by the end of 2010? Tweet this 

Despite significantly weaker margins realized in 2009, Murphy Oil (MUR $50.75) intends to add a combined 80 new gas stations to its network of Murphy USA sites, located at Wal Mart supercenters, and its stand alone Murphy express outlets. In 2009, the company added 26 new filling stations The integrated energy company derives about 69 percent of annual sales ($19 billion in 2009) from its US refining and marketing operations 
Share:  <span class="sent">Despite significantly weaker margins realized in 2009, <span class="company">Murphy Oil</span> (MUR $50.75) intends to add a combined 80 new gas stations to its network of Murphy USA sites, located at Wal Mart supercenters, and its stand alone Murphy express outlets. </span> In 2009, the company added 26 new filling stations The integrated energy company derives about 69 percent of annual sales ($19 billion in 2009) from its US refining and marketing operations Tweet this 

Ivanka Trump and her father "The Donald" have allied with bondholders of bankrupt Trump Entertainment Resorts (TRMPQ $0.08), to compete with a plan crafted from senior lender Beal Bank and its new partner, the legendary billionaire Carl Icahn, in salvaging the operations of the bankrupt gaming company. Her significant assets aside, given the Trump family's dismal past performance in running casinos in Atlantic City, might the Trump Taj Mahal, Trump Plaza and Trump Marina be in better hands with just about anyone else? Read More at BNET Media… Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article 
Share:  <span class="sent">Ivanka Trump and her father "The Donald" have allied with bondholders of bankrupt <span class="company">Trump Entertainment Resorts</span> (TRMPQ $0.08), to compete with a plan crafted from senior lender Beal Bank and its new partner, the legendary billionaire Carl Icahn, in salvaging the operations of the bankrupt gaming company. </span> Her significant assets aside, given the Trump family's dismal past performance in running casinos in Atlantic City, might the Trump Taj Mahal, Trump Plaza and Trump Marina be in better hands with just about anyone else? Read More at BNET Media… Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article Tweet this 

The motive behind Cephalon's (CEPH $65.00) recent patent infringement lawsuits is clear: litigate to slow the market entrance of cheaper copycat versions while it continues to transition patients from its older narcolepsy drug Provigil (modafinil) to Nuvigil. Cephalon derived 51 percent of total sales, or almost $925 million, from its Provigil franchise in 2008 However, the clock winding down prior to any judicial decision(s) is an overhang for Cephalon — and could rip apart the planned Provigil to Nuvigil entrenchment campaign: cheaper copycats of Provigil will flood US pharmacy shelves come — just about the time both Teva Pharmaceuticals and Mylan Labs could decide to launch "at risk" (liable for damages if court invalidates their patent challenges) copies of Nuvigil, alongside their legal introductions of Provigil 
Share:  <span class="sent">The motive behind <span class="company">Cephalon</span>'s (CEPH $65.00) recent patent infringement lawsuits is clear: litigate to slow the market entrance of cheaper copycat versions while it continues to transition patients from its older narcolepsy drug Provigil (modafinil) to Nuvigil. </span> <span class="company">Cephalon</span> derived 51 percent of total sales, or almost $925 million, from its Provigil franchise in 2008 However, the clock winding down prior to any judicial decision(s) is an overhang for <span class="company">Cephalon</span> — and could rip apart the planned Provigil to Nuvigil entrenchment campaign: cheaper copycats of Provigil will flood US pharmacy shelves come — just about the time both Teva Pharmaceuticals and Mylan Labs could decide to launch "at risk" (liable for damages if court invalidates their patent challenges) copies of Nuvigil, alongside their legal introductions of Provigil Tweet this 

When asked in an interview on the business channel CNBC today if its new oral treatment for MS, Ampyra, would cost between $5,000 to $10,000 a year, Acorda Therapeutics (ACOR $28.00) CEO Cohen deferred, hinting only that the cost would be a factor of demand and the invested cost to bring the drug to market. The company is positioned to jump out of the gate come the March launch At , the company already had a specialty sales force of 73 sales professionals in place, salivating to call on high volume (RX) prescribers and other influential neurologists who specialize in treating patients with neuromuscular disorders 
Share:  <span class="sent">When asked in an interview on the business channel CNBC today if its new oral treatment for MS, Ampyra, would cost between $5,000 to $10,000 a year, <span class="company">Acorda Therapeutics</span> (ACOR $28.00) CEO Cohen deferred, hinting only that the cost would be a factor of demand and the invested cost to bring the drug to market. </span> The company is positioned to jump out of the gate come the March launch At , the company already had a specialty sales force of 73 sales professionals in place, salivating to call on high volume (RX) prescribers and other influential neurologists who specialize in treating patients with neuromuscular disorders Tweet this